natgillin/translations-raw huggingface dataset:
Rasitrio 300 mg/5 mg/25 mg филмирани таблетки Алискирен/амлодипин/хидрохлоротиазид (Aliskiren/amlodipine/hydrochlorothiazide)
Rasitrio 300 mg/5 mg/25 mg film-coated tablets Aliskiren/amlodipine/hydrochlorothiazide
Rasitrio 300 mg/5 mg/25 mg филмирани таблетки са бледооранжево-кафяви, овални таблетки с вдлъбнато релефно означение “OIO” от едната страна и “NVR” от другата страна.
Rasitrio 300 mg/5 mg/25 mg film-coated tablets are pale orange-brown, oval tablets, with “OIO” debossed on one side and “NVR” on the other.
Rasitrio е противопоказан при пациенти с тежко чернодробно увреждане (вж. точка 4.3).
Rasitrio is contraindicated in patients with severe hepatic impairment (see section 4.3).
Rasitrio е проучен в двойно-сляпо, рандомизирано, активно-контролирано проучване при 1 181 пациенти, от които 773 са били класифицирани като такива с умерена хипертония (ссСАН 160-180 mmHg), а 408 - като такива с тежка хипертония (ссСАН >180 mmHg), в
Rasitrio was studied in a double-blind, randomised, active-controlled study in 1,181 patients of which 773 were classified as moderately hypertensive (msSBP 160-180 mmHg) and 408 as severely hypertensive (msSBP >180 mmHg) at baseline.
Rasitrio не се препоръчва по време на ранна бременност и не трябва да се приема, ако сте бременна след 3- ия месец, тъй като може да причини сериозно увреждане на Вашето бебе, ако се употребява през този период (вижте раздел “Бременност”).
Rasitrio is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see Pregnancy section).
Rasitrio съдържа три активни вещества – алискирен, амлодипин и хидрохлоротиазид.
Rasitrio contains three active substances, aliskiren, amlodipine, and hydrochlorothiazide.
Ratiograstim 30 MIU/0,5 ml
Ratiograstim 30 MIU/0.5 mL
Ratiograstim 30 MIU/0,5 ml инжекционен или инфузионен разтвор
Ratiograstim 30 MIU/0.5 mL solution for injection or infusion
Ratiograstim 30 MIU/0,5 ml инжекционен или инфузионен разтвор Ratiograstim 48 MIU/0,8 ml инжекционен или инфузионен разтвор
Ratiograstim 30 MIU/0.5 mL solution for injection or infusion Ratiograstim 48 MIU/0.8 mL solution for injection or infusion
Ratiograstim 30 MIU/0,5 ml инжекционен или инфузионен разтвор Филграстим
Ratiograstim 30 MIU/0.5 mL solution for injection or infusion Filgrastim
Ratiograstim 48 MIU/0,8 ml
Ratiograstim 48 MIU/0.8 mL
Ratiograstim 48 MIU/0,8 ml инжекционен или инфузионен разтвор
Ratiograstim 48 MIU/0.8 mL solution for injection or infusion
Ratiograstim 48 MIU/0,8 ml инжекционен или инфузионен разтвор Филграстим
Ratiograstim 48 MIU/0.8 mL solution for injection or infusion Filgrastim
Ratiograstim e „биоподобно“ лекарство.
Ratiograstim is a ‘biosimilar’ medicine.
Ratiograstim е инжекционен или инфузионен разтвор в предварително напълнена спринцовка със или без обезопасяващо устройство.
Ratiograstim is a solution for injection or infusion in a pre-filled syringe with or without safety device.
Ratiograstim е полезен при следните болестни състояния:
Ratiograstim is useful in several different conditions, which are:
Ratiograstim и костномозъчна трансплантация
Ratiograstim and bone marrow transplantation
Ratiograstim и мобилизация на периферни кръвни стволови клетки
Ratiograstim and peripheral blood stem cell mobilisation
Ratiograstim и неутропения при пациенти с HIV инфекция
Ratiograstim and neutropenia in patients with HIV infection
Ratiograstim и тежка хронична неутропения
Ratiograstim and severe chronic neutropenia
Ratiograstim и химиотерапия
Ratiograstim and chemotherapy
Ratiograstim не е изпитван при бременни жени.
Ratiograstim has not been tested in pregnant women.
Ratiograstim не съдържа никакви консерванти.
Ratiograstim does not contain any preservative.
Ratiograstim съдържа активното вещество филграстим.
Ratiograstim contains the active substance filgrastim.
Ratiograstim съдържа сорбитол и натрий
Ratiograstim contains sorbitol and sodium
Ratiograstim съдържа сорбитол.
Ratiograstim contains sorbitol.
Ravi jooksul jälgitakse teie maksafunktsiooni hoolikamalt.
During treatment your liver functions will be monitored more closely.
Ravi keskmine kestus oli täiskasvanute populatsioonis (N=798) 19 päeva mikafungiiniga ja 18 päeva flukonasooliga ja lastel (N=84) mõlemas ravirühmas 23 päeva.
The mean period of treatment was 19 days for micafungin and 18 days for fluconazole in the adult population (N=798) and 23 days for both treatment arms in the paediatric population (N=84).
Ravi keskmine kestusaeg oli 14 päeva ning ööpäevase annuse keskmine mikafungiini korral (n=260) oli 150 mg ja flukonasooli korral (n=258) 200 mg.
The median treatment duration was 14 days and the median average daily dose was 150 mg for micafungin (N=260) and 200 mg for fluconazole (N=258).
Ravi kestus
Treatment duration
Ravi lõpus täheldati endoskoopilise leiu 0 astet (endoskoopilist paranemist) 87,7% (228/260) mikafungiini ja 88,0% (227/258) flukonasooli rühma patsientidest (erinevuse 95% usalduspiirid: [-5,9%, 5,3%]).
An endoscopic grade of 0 (endoscopic cure) at the end of treatment was observed for 87.7% (228/260) and 88.0% (227/258) of patients in the micafungin and fluconazole groups, respectively (95% CI for difference: [-5.9%, 5.3%]).
Ravi mikafungiiniga võib läbi viia ainult hoolika riski/kasu analüüsi alusel, eriti patsientidel, kellel on raske maksafunktsiooni häire või mõni krooniline maksahaigus, mis on teadaolevalt preneoplastiline seisund, näiteks kaugelearenenud maksafibroos, tsirroos, viirushepatiit, vastsündinute maksahaigus või kaasasündinud ensüümidefektid, või kes saavad samaaegset ravi hepatotoksiliste ja/või genotoksiliste omadustega ravimitega.
Micafungin treatment should be conducted on a careful risk/benefit basis, particularly in patients having severe liver function impairment or chronic liver diseases known to represent preneoplastic conditions, such as advanced liver fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects, or receiving a concomitant therapy including hepatotoxic and/or genotoxic properties.
Ravi võib alustada enne külvi ja teiste laboratoorsete uuringute tulemuste selgumist.
Therapy may be instituted before the results of the cultures and other laboratory studies are known.
RAVICTI 1,1 g/ml
RAVICTI 1.1 g/ml
RAVICTI 1,1 g/ml перорална течност
RAVICTI 1.1 g/ml oral liquid
RAVICTI 1,1 g/ml перорална течност Глицерол фенилбутират
RAVICTI 1.1 g/ml oral liquid Glycerol phenylbutyrate
Ravicti е лекарство с удължено освобождаване, което означава, че активното вещество се освобождава равномерно през деня.
Ravicti is a sustained-release medicine, meaning the active substance is released evenly during the day.
Ravicti е лекарство, което се използва за хронично лечение на нарушения в цикъла на уреята при възрастни и деца на възраст от два месеца, когато заболяванията не могат да бъдат контролирани само с промени в хранителния режим.
Ravicti is a medicine used long-term to manage urea-cycle disorders in adults and children from the age of two months, when the diseases cannot be managed by changes in their diet alone.
RAVICTI е показан за употреба като допълнителна терапия при хронично лечение на възрастни и педиатрични пациенти на възраст ≥2 месеца с нарушения на цикъла на уреята (urea cycle disorders, UCDs), включително с дефицит на карбамил фосфат синтаза I (carbamoyl phosphate- synthase-I, CPS), орнитин карбомоилтрансфераза (ornithine carbamoyltransferase, OTC), аргининосукцинат синтетаза (argininosuccinate synthetase, ASS), аргининосукцинат лиаза (argininosuccinate lyase, ASL), аргиназа I (arginase, ARG) и орнитин транслоказа (синдром на дефицита на хиперорнитинемия-хипермониемия хомоцитрулинурия (hyperornithinaemia- hyperammonaemia homocitrullinuria, ННН), които не могат да се овладеят като се ограничава храната, богата на протеини, и/или само с добавка на аминокиселина.
RAVICTI is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
RAVICTI може да повлиява в значителна степен способността за шофиране и работа с машини, като се има предвид, че лечението с глицерол фенилбутират може да причини замаяност или главоболие (вж. точка 4.8).
RAVICTI may have major influence on the ability to drive and use machines given that treatment with glycerol phenylbutyrate may cause dizziness or headaches (see section 4.8).
RAVICTI може да се добави към малко количество меки храни, като кетчуп, лечебни храни, ябълково пюре или тиквено пюре.
RAVICTI can be added to a small amount of soft foods, such as ketchup, medical formulas, apple sauce or squash.
RAVICTI може да се добави към малко количество ябълков сос, кетчуп или тиквено пюре и трябва да се използва в рамките на 2 часа, когато се съхранява на стайна температура (25° C).
RAVICTI may be added to a small amount of apple sauce, ketchup, or squash and should be used within 2 hours when stored at room temperature (25° C).
RAVICTI не се препоръчва да се използва при деца на възраст под 2 месеца.
RAVICTI is not recommended for use in children under 2 months of age.
Ravicti не трябва да се използва за лечение на остра хиперамонемия (внезапно повишаване на нивата на амоняк в кръвта).
Ravicti must not be used for the treatment of acute hyperammonaemia (sudden rise of blood ammonia levels).
Ravicti се използва при пациенти, които имат недостиг на един или повече от следните ензими: карбамил фосфат синтаза I, орнитин карбомоилтрансфераза, аргининосукцинат синтетаза, аргининосукцинат лиаза, аргиназата I и орнитин транслоказа.
Ravicti is used in patients who lack one or more of the following enzymes: carbamoyl phosphate synthase-I, ornithine carbamoyltransferase, argininosuccinate synthetase, argininosuccinate lyase, arginase I and ornithine translocase.
RAVICTI съдържа активното вещество „глицерол фенилбутират“, което се използва за лечение на шестте известни „нарушения на цикъла на уреята “ при възрастни и деца на възраст 2 месеца и повече.
RAVICTI contains the active substance ‘glycerol phenylbutyrate’which is used to treat six known ‘urea cycle disorders’ (UCDs) in adults and children aged 2 months and over.
RAVICTI трябва да се използва със специална нископротеинова диета.
RAVICTI must be used with a special low protein diet.
RAVIMI VÄLJASTAMISTINGIMUSED
GENERAL CLASSIFICATION FOR SUPPLY
Ravimi väljakirjutaja loetelu
Prescriber checklist
RAVIMPREPARAADI NIMETUS
NAME OF THE MEDICINAL PRODUCT
RAVIMPREPARAADI NIMETUS
SUMMARY OF PRODUCT CHARACTERISTICS
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
RAVIMVORM
PHARMACEUTICAL FORM
RAVIMVORM JA PAKENDI SUURUS
PHARMACEUTICAL FORM AND CONTENTS
Ravnajte natančno po veterinarjevih navodilih.
Please carefully follow the instructions of the veterinarian.
Ravni trigliceridov LDL in VLDL se znižajo.
LDL and VLDL triglycerides are reduced.
Raxone (N = 53)
Raxone (N=53)
Raxone 150 mg филмирани таблетки
Raxone 150 mg film-coated tablets
Raxone 150 mg филмирани таблетки идебенон
Raxone 150 mg film-coated tablets idebenone
Raxone 150 mg филмирани таблетки идебенон (idebenone)
Raxone 150 mg film-coated tablets idebenone
Raxone в RHODOS (N=53)
RHODOS Raxone (N=53)
Raxone е лекарство, което се използва за лечение на зрително увреждане при възрастни и юноши на 12 години и по-големи с наследствена оптична невропатия на Лебер (LHON) — наследствено заболяване, което се характеризира с прогресивна загуба на зрение.
Raxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber’s hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight.
Raxone е показан за лечението на зрително увреждане при юноши и възрастни пациенти с наследствена оптична невропатия на Лебер (LHON) (вж. точка 5.1).
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON) (see section 5.1).
Raxone е разрешен за употреба при „извънредни обстоятелства“.
Raxone has been authorised under ‘exceptional circumstances’.
Raxone е „хибридно лекарство“.
Raxone is a ‘hybrid medicine’.
Raxone може да премине в кърмата.
Raxone may pass into the mother’s milk.
Raxone не повлиява или повлиява пренебрежимо способността за шофиране и работа с машини.
Raxone has no or negligible influence on the ability to drive and use machines.
Raxone се отпуска по лекарско предписание и лечението трябва да започне и да се наблюдава от лекар с опит в лечението на LHON.
Raxone can only be obtained with a prescription and treatment should be started and supervised by a doctor with experience in LHON.
Raxone се предлага в бели, пластмасови бутилки.
Raxone is supplied in white plastic bottles.
Raxone се предлага под формата на таблетки от 150 mg и препоръчителната доза е две таблетки за прием три пъти дневно с храна.
Raxone is available as 150 mg tablets, and the recommended dose is two tablets taken three times a day with food.
Raxone съдържа лактоза (вид захар).
Raxone contains lactose (a type of sugar).
Raxone съдържа лактоза и сънсет жълто (E110)
Raxone contains lactose and sunset yellow (E110)
Raxone съдържа оцветител, наречен „сънсет жълто“ (наричан също E110).
Raxone contains a colourant called “sunset yellow” (also called E110).
Raziskava je bila opravljena pri bolnikih, pri katerih je po zdravljenju s terapijo prve izbire prišlo do relapsa (srednji čas do progresije, ki je minil od zdravljenja s terapijo prve izbire: 84 dni za zdravljenje s peroralnim topotekanom v kombinaciji z NPO; 90 dni za zdravljenje z NPO samo) in pri katerih zdravljenje z intravensko obliko kemoterapije ni bilo primerno.
A phase III trial (study 478) compared oral topotecan plus Best Supportive Care (BSC) (n=71) with BSC alone (n=70) in patients who had relapsed following first line therapy (median time to progression [TTP] from first-line therapy: 84 days for oral topotecan + BSC, 90 days for BSC) and for whom retreatment with intravenous chemotherapy was not considered appropriate.
Raziskava, ki je preučevala farmakodinamične interakcije, je pokazala, da lahko uporaba kortikosteroidov, ki se dajejo pred PDT ali sočasno z njim, da bi zmanjšali nastanek zoženja, zmanjša varnost zdravljenja.
It is possible that concomitant use of other photosensitising agents (e.g., tetracyclines, sulphonamides, phenothiazines, sulphonylurea hypoglycaemic agents, thiazide diuretics, griseofulvin and fluoroquinolones) could increase the photosensitivity reaction.
Raziskave in vitro ter in vivo so pokazale, da meloksikam močneje zavira ciklooksigenazo 2 (COX-2) kot ciklooksigenazo 1 (COX-1).
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
Raziskave na kuncih in podganah so pokazale, da topotekan povzroča smrt zarodka oziroma ploda.
Topotecan was also shown to cause embryo-foetal lethality when given to rats and rabbits.
Raziskave o vplivu zdravila na sposobnost vožnje in upravljanje s stroji niso bile izvedene.
No studies on the effects on the ability to drive and use machines have been performed.
Raziskave toksičnosti po večkratnih odmerkih so pokazale, da pramipeksol kaže funkcionalne učinke, večinoma na osrednji živčni sistem in ženski reproduktivni sistem, ki so verjetno posledica povečanega farmakodinamskega učinka pramipeksola.
Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and female reproductive system, and probably resulting from an exaggerated pharmacodynamic effect of pramipexole.
razjeda na črevesju, nenormalna odprtina med sapnikom in požiralnikom
lesion in intestine, abnormal opening between the wind pipe and the food pipe
Razlika v deležu kliničnih odzivov in remisij je bila pri bolnikih, ki so prejemali ustekinumab, statistično značilna že v 3. tednu in se je povečevala do 8. tedna.
Clinical response and remission were significant as early as week 3 in ustekinumab treated patients and continued to improve through week 8.
Razlike med azijskimi in zahodnimi populacijami, ki so posledica polimorfizma encima CYP2A6, niso glavni dejavnik za različne vrednosti MTD (največji tolerančni odmerek) med populacijami.
Therefore, the CYP2A6 polymorphism differences between Asian and Western populations do not appear to be the key determinant for differences in the MTD between populations.
Razlitje in odstranjevanje
Spills and disposal
Razmerje bolnikov brez bruhanja v 0-72 urah po operaciji je bilo podobno pri uporabi palonosetrona 1 µg/kg (88 %) in 3 µg/kg (84 %).
The proportion of patients without emesis during 0-72 hours post-operatively was similar after palonosetron 1 μg/kg or 3 μg/kg (88% vs 84%).
Razmerje tveganja (95 % IZ)
Hazard ratio (95% C.I.)
Razmerje tveganja (95 % IZ)
Hazard ratio (95% CI)
Razmerje tveganja (95-% IZ)
Hazard Ratio [95% CI]
Razmerje tveganja za preživetje z intravenskim topotekanom relativno glede na kombinacijo CAV je bilo 1,04 (95 % interval zaupanja: 0,78 – 1,40).
The hazard ratio for survival of IV topotecan relative to CAV was 1.04 (95 % CI 0.78 – 1.40).
Razmisliti je treba o začasni prekinitvi zdravljenja z zoledronsko kislino, dokler se stanje ne razreši in dokler se ne zmanjša vpliv vpletenih dejavnikov tveganja, če je to mogoče doseči.
Temporary interruption of zoledronic acid treatment should be considered until the condition resolves and contributing risk factors are mitigated where possible.
razpad mišic (rabdomioliza), nekateri primeri težav s kitami, pri katerih včasih pride do zapleta s
Muscle breakdown (rhabdomyolysis), some cases of tendon problems, sometimes complicated by rupture.
razpadanje mišic
muscle breakdown
Razpolovna doba izločanja meloksikama je 24 ur.
Meloxicam is eliminated with a half-life of 24 hours.
Razpolovna doba topotekana se je podaljšala za 30 %, volumen porazdelitve pa se ni bistveno spremenil.
Topotecan half-life was increased by about 30 % but no clear change in volume of distribution was observed.
Razpolovna doba topotekana se je podaljšala za 30 %, volumen porazdelitve pa se ni bistveno spremenil.
Topotecan half-life was increased by about 30% but no clear change in volume of distribution was observed.
Razpolovni čas (t1/2) izločanja variira od 8 ur pri mladih do 12 ur pri starejših ljudeh.
The elimination half-life (t½) varies from 8 hours in the young to 12 hours in the elderly.
Razpolovni čas izločanja glavnega (neaktivnega) krožečega metabolita je bil 8 ur po enkratnem in večkratnem dajanju.
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Razpoložljivi farmakodinamski/toksikološki podatki pri živalih kažejo na izločanje zdravila Teysuno/presnovkov v mleko (za podrobnosti glejte poglavje 5.3).
Available pharmacodynamic/toxicological data in animals have shown excretion of Teysuno or its metabolites in milk (for details see section 5.3).
Razpredelnica z neželenimi učinki
Tabulated list of adverse reactions
Razredčena raztopina
Diluted solution
Razredčeno raztopino infundirajte bolniku v času, ki naj ne bo krajši od ene ure.
Administer the diluted solution over a period of at least one hour.
Razredčeno raztopino infundirajte bolniku v času, ki naj ne bo krajši od ene ure.
Infuse the diluted solution over a period of at least one hour.
Razredčeno raztopino za infundiranje ali neuporabljeno zdravilo, ki ostane v viali in brizgi, je treba zavreči v skladu z lokalnimi predpisi.
Any diluted infusion solution or unused product remaining in the vial and the syringe should be thrown away in accordance with local requirements.
Razredčite pred uporabo.
Dilute before use
Raztopina je bistra do rahlo opalescentna in brezbarvna do svetlo rumena ter lahko vsebuje nekaj majhnih prosojnih ali belih beljakovinskih delcev.
The solution is clear to slightly opalescent, colourless to light yellow and may contain a few small translucent or white particles of protein.
Raztopina je bistra do rahlo opalescentna in brezbarvna do svetlo rumena.
The solution is clear to slightly opalescent, colourless to light yellow.
Raztopina je bistra, brezbarvna do svetlo rumena.
The solution is clear, colourless to light yellow.
Raztopina je bledo rumena, s koncentracijo 1 mg topotekana na ml.
The concentrate is pale yellow in colour and contains 1 mg per ml of topotecan.
Raztopina lahko vsebuje nekaj majhnih, prosojnih ali belih beljakovinskih delcev.
The solution may contain a few small translucent or white particles of protein.
raztopina za
injection
raztopina za injiciranje
Solution for injection
raztopina za injiciranje 1 viala
Solution for injection 1 vial
raztopina za injiciranje 45 mg/0,5 ml
Solution for injection 45 mg/0.5 mL
raztopina za injiciranje 90 mg/1 ml
Solution for injection 90 mg/1 mL
raztopina za injiciranje v napolnjeni injekcijski brizgi 45 mg/0,5 ml
Solution for injection in pre-filled syringe 45 mg/0.5 mL
raztopina za injiciranje v napolnjeni injekcijski brizgi 90 mg/1 ml
Solution for injection in pre-filled syringe 90 mg/1 mL
Raztopina za injiciranje.
Solution for injection.
Raztopine ne smete uporabiti, če vsebuje vidne neprozorne ali tuje delce ali če je spremenjene barve.
Do not use if visibly opaque particles, discoloration or foreign particles are observed.
Raztopine pemetrekseda so namenjene samo enkratni uporabi.
Pemetrexed solutions are for single use only.
Raztopine pemetrekseda za infundiranje, pripravljene, kot je navedeno zgoraj, so skladne s seti za dajanje in infuzijskimi vrečkami iz polivinilklorida in prevlečenimi s poliolefinom.
Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chloride- and polyolefin- lined administration sets and infusion bags.
Raztopine v viali ali napolnjeni injekcijski brizgi zdravila STELARA ne smete stresati.
The solution in the STELARA vial or pre-filled syringe should not be shaken.
Raztopine v viali zdravila STELARA ne smete stresati.
The solution in the STELARA vial should not be shaken.
raztopino za injiciranje uporaba
Intravenous use
razširjena koagulacija in krvavitev
widespread blood clotting and bleeding
rbenje (‘pruritus’)
Itching (‘pruritus’)
RBV
24 weeks
RBV = рибавирин; в.
RBV = ribavirin; c.
RCP FeLV
FeLV
RCTU скор
RCTU score
rd Klm National Road Athens‐Lamia 65 Agios Stefanos
rd Klm National Road Athens-Lamia 65 Agios Stefanos
Rdečkastorjavo raztopino počasi injicirajo v veno na vaši roki 3 do 5 minut.
The reddish-brown solution is slowly injected, over 3 to 5 minutes, into a vein.
RE-MEDY показва, че лечението с дабигатран етексилат 150 mg два пъти дневно е не по-малко ефикасно от варфарин (не по-малка ефективност: 2,85 за коефициент на риска и 2,8 за разлика в риска).
RE-MEDY demonstrated that treatment with dabigatran etexilate 150 mg twice daily was non-inferior to warfarin (non-inferiority margin 2.85 for hazard ratio and 2.8 for risk difference).
RE-MEDY показва, че лечението с дабигатран етексилат 150 mg два пъти дневно е не по-малко ефикасно от варфарин (не по-малка ефективност: 2,85 за коефициент на риска и 2,8 за разлика в риска).
RE-MEDY demonstrated that treatment with dabigatran etexilate 150 mg twice daily was non-inferior to warfarin non-inferiority margin: 2.85 for hazard ratio and 2.8 for risk difference).
RE-MODEL (коляно)
RE-MODEL (knee)
RE-NOVATE (тазобедрена става)
RE-NOVATE (hip)
Reakcie v mieste podania
Injection site reactions
Reakcija akutne faze
Acute phase reaction
reakcija na mestu injiciranja*
Injection site reaction
Reakcije so bile blage, specifično zdravljenje pa običajno ni bilo potrebno.
Reactions have been mild and have not generally required specific therapy.